

References

- Ablon, J. 2002. The nature of stigma and medical conditions. *Epilepsy & Behaviour* 3(6), Supplement 2:2–9.
- ACMG (American College of Medical Genetics). 2005. *Newborn screening: Toward a uniform screening panel and system*. Rockville, MD: Maternal and Health Care Bureau. Also available at URL: <http://mchb.hrsa.gov/screening>.
- Adelswärd, V., and L. Sachs. 2002. *Framtida skuggor: Samtal om risk, prevention och den genetiska familjen (Future shadows: Conversations on risk, prevention and the genetic family)*. Arkiv förlag: Lund.
- Andermann, A., I. Blanquaert, S. Beauchamp, and V. Déry. 2008. Revisiting Wilson and Jungner in the genomic age: A review of screening criteria over the past 40 years. *Bulletin of the World Health Organization* 86(4):317–319.
- Annes, J.P., M.A. Giovanni, and M.F. Murray. 2010. Risks of presymptomatic direct-to-consumer genetic testing. *New England Journal of Medicine* 363(12):1100–1101.
- Asch, A. 2002. Disability, equality, and prenatal testing: Contradictory or compatible? *Florida State University Law Review* 30:315–342.
- Ashcroft, R.E., A. Dawson, H. Draper, and J.R. McMillan (eds.) 2007. *Principles of health care ethics*, 2nd edition. Chichester: Wiley.
- Bailey, D.B., Jr., D. Skinner, and S.F. Warren. 2005a. Newborn screening for developmental disabilities: Reframing presumptive benefit. *American Journal of Public Health* 11:1889–1893.
- Bailey, D.B., Jr., D. Skinner, and K.L. Sparkman. 2005b. Discovering fragile X syndrome: Family experiences and perceptions. *Pediatrics* 2:407–416.
- Bailey, D.B., Jr., D. Skinner, A.M. Davis, I. Whitmarsh, and C. Powell. 2008. Ethical, legal, and social concerns about expanded newborn screening: Fragile X syndrome as a prototype for emerging issues. *Pediatrics* 3:693–704.
- Baily, M.A., and T.H. Murray. 2008. Ethics, evidence, and cost in newborn screening. *Hastings Center Report* 3:23–31.
- Barry, B. 1991. *Theories of justice*. Berkeley, CA: University of California Press.
- Battin, M.P., L.P. Francis, J.A. Jacobson, and C.B. Smith. 2008. *The patient as victim and vector: Ethics and infectious disease*. Oxford: Oxford University Press.
- Beauchamp, T.L., and J.F. Childress. 2001. *Principles of biomedical ethics*, 5th edition. New York, NY and Oxford: Oxford University Press.
- Benn, P.A., and A.R. Chapman. 2010. Ethical challenges in providing noninvasive prenatal diagnosis. *Current Opinion in Obstetrics and Gynecology* 22:128–134.

- Boorse, C. 1997. A rebuttal on health. In *What is disease?*, eds. J. Humber and R. Almeder, 3–134. Totowa, NJ: Humana Press.
- Brandon, K. 2009. 12.6 million is a BIG number. *The white house blog*. Online access: <http://www.whitehouse.gov/blog/126-Million-is-a-BIG-Number/>. Accessed 11 Aug 2009.
- Broberg, G., and N. Roll-Hansen. 2005. *Eugenics and the welfare state: Sterilization policy in Denmark, Sweden, Norway, and Finland*. East Lansing, MI: Michigan State University Press.
- Buchanan, A., D.W. Brock, N. Daniels, and D. Wikler. 2000. *From chance to choice – Genetics and justice*. Cambridge: Cambridge University Press.
- Bui, T.H., and M. Nordenskjöld. 2002. Prenatal diagnosis: Molecular genetics and cytogenetics. *Best Practice Research in Clinical Obstetrics and Gynaecology* 16: 629–643.
- Chadwick, R., D. Shickle, H. ten Have, and U. Wiesing. (eds.) 1999. *The ethics of genetic screening*. Dordrecht: Kluwer Academics Publishers.
- Chalmers, D. 2005. *Genetic testing and the criminal law*. London: Routledge and Chapman & Hall.
- Childress, J.F., R.R. Faden, R.D. Gaare, L.O. Gostin, J. Kahn, R.J. Bonnie, et al. 2002. Public health ethics: Mapping the Terrain. *Journal of Law, Medicine & Ethics* 30(2):170–178.
- Chiu, R.W.K., R. Akolekar, Y.W.L. Zheng, T.Y. Leung, H. Sun, K.C.A. Chan, et al. 2011. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: Large scale validity study. *BMJ* 342:c7401.
- CIOMS. 2002. *International ethical guidelines for biomedical research involving human subjects*. Geneva: World Health Organisation.
- Clarke, A. (ed.) 1994. *Genetic counselling: Practice and principles*. London: Routledge.
- Clarke, A. 1998. Genetic counselling. *Encyclopaedia of applied ethics, Volume 2*. San Diego, CA: Academic Press.
- Coggon, J. 2010. Does public health have a personality (and if so, does it matter if you don't like it)? *Cambridge Quarterly of Healthcare Ethics* 19:235–248.
- Connor, M., and M. Ferguson-Smith. 1997. *Essential medical genetics*. Oxford: Blackwell Science Ltd.
- Coutts, M.C. 1990. Maternal-fetal conflict: Legal and ethical issues. *Scope notes: Annotated bibliographies from the bioethics research library*, No. 14. Available online: <http://bioethics.georgetown.edu/publications/scopenotes/sn14.pdf>. Accessed 28 Oct 2010.
- Daniels, N. 2007. *Just health: Meeting health needs fairly*. Cambridge: Cambridge University Press.
- Danish Council of Ethics. 1999. *Screening – A report*. Copenhagen: The Danish Council of Ethics.
- Davis, T.C., S.G. Humiston, C.L. Arnold, J.A. Bocchini Jr., P.F. Bass 3rd, E.M. Kennen, et al. 2006. Recommendations for effective newborn screening communication: Results of focus groups with parents, providers, and experts. *Pediatrics* 117:326–340.
- Dawson, A. 2005. The determination of “best interest” in relation to childhood vaccinations. *Bioethics* 19(2):187–205.
- Dawson, A. 2007. Vaccination ethics. In *Principles of health care ethics*, eds. R.E. Achcroft, A. Dawson, H. Draper, and J.R. McMillan. Chichester: Wiley.

- Dawson, A. (ed.) 2011. *Public health ethics: Key concepts and issues in policy and practice*. Cambridge: Cambridge University Press.
- Dawson, A., and M. Verweij. 2007a. The meaning of 'public' in 'public health'. In *Ethics, prevention, and public health*, eds. A. Dawson and M. Verweij. Oxford: Oxford University Press.
- Dawson, A., and M. Verweij. (eds.) 2007b. *Ethics, prevention, and public health*. Oxford: Oxford University Press.
- Deans, Z., and A.J. Newson. 2010. Should non-invasiveness change informed consent procedures for prenatal diagnosis? *Health Care Analysis*, 2010 Mar 9. [Epub ahead of print, doi: 10.1007/s10728-010-0146-8]
- de Jong, A., W.J. Dondorp, C.E. de Die-Smulders, S.G. Frints, and G.M. de Wert. 2010. Non-invasive prenatal testing: Ethical issues explored. *European Journal of Human Genetics* 18:272–277.
- Denham, J.W., R. Bender, and W.E. Paradise. 2010. It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials. *Medical Journal of Australia* 192(7), 393–396.
- Dew-Hughes, D. (ed.) 2003. *Educating children with Fragile X syndrome. A multi-professional view*. London: Routledge. DnaDirect. Webportal to commercial genetic services. Online access: <http://www.dnadirect.com/web/consumers>. Last accessed 29 Oct 2010.
- Domenghetti, G., B. D'Avanzo, M. Egger, F. Berrino, T. Perneger, P. Mosconi, et al. 2003. Women's perception of the benefits of mammography screening: Population-based survey in four countries. *International Journal of Epidemiology* 32:816–821.
- Duffy, S.W., T. László, and R.A. Smith. 2002. The mammography screening trials: Commentary on the recent work by Olson and Götzcshe. *Journal of Surgical Oncology* 81:159–166 (discussion 162–166).
- Eddy, D.M. 1990. Anatomy of a decision. *Journal of the American Medical Association* 263:441.
- ESHG (European Society of Human Genetics). 2003. Population genetic screening programmes: Technical, social and ethical issues. Recommendations of the European Society of Human Genetics. *European Journal of Human Genetics* 11:5–7.
- Esserman, L., Y. Shieh, and I. Thompson. 2009. Rethinking screening for breast cancer and prostate cancer. *JAMA* 302:1685–1692.
- Evans, J.P., D.C. Dale, and C. Fomous. 2010. Preparing for a consumer-driven genomic age. *New England Journal of Medicine* 363(12):1099–1103.
- Fang, F., N.L. Keating, L.A. Mucci, H.O. Adami, M.J. Stampfer, U. Valdimarsdóttir, and K. Fall. 2010. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: Cohort study in the United States. *Journal of the National Cancer Institute* 102(5):307–314.
- Favre, R., N. Duchange, C. Vayssière, M. Kohler, N. Bouffard, M.C. Hunsinger, et al. 2007. How important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: A French study. *Prenatal Diagnosis* 3:197–205.
- Fraser, F.C. 1974. Genetic counseling. *American Journal of Human Genetics* 26: 636–659.
- Freedman, D.A., D.B. Petitti, and J.M. Robins. 2004. On the efficacy of screening for breast cancer. *International Journal of Epidemiology* 33:43–55.

- Friedman, M. 1970. The social responsibility of business is to increase its profits. *The New York Times Magazine*, September 13, 1970.
- Friedman Ross, L. 2011. Mandatory versus voluntary consent for newborn screening? *Kennedy Institute of Ethics Journal* 20(4):299–328.
- Genetic Integrity Act. Swedish code of statutes no 2006:351. Available online: <http://www.smer.se/bazment/266.aspx>
- Gianroli, L., M.C. Magli, A. Feraretti, and S. Munné. 1999. Preimplantation diagnosis for aneuploidies in patients undergoing in vitro fertilization with a poor prognosis: Identification of the categories for which it should be proposed. *Fertility and Sterility* 72:837–844.
- Glover, J. 1977. *Causing death and saving lives*. London: Penguin Books.
- Glover, J. 2006. *Choosing children: Genes, disability, and design*. Oxford: Clarendon Press.
- Gregg, A.R., and J.L. Simpson. 2002. Genetic screening for cystic fibrosis. *Obstetrics and Gynecology Clinics of North America* 29:329–340.
- Gøtzsche, P.C., and K.J. Jørgensen. 2009a. Ärlig information om mammografiscreening, tack! (Honest information about mammography screening, please!). *Läkartidningen* 44:2860–2861.
- Gøtzsche, P.C., and K.J. Jørgensen. 2009b. Överdiagnostik vid mammografiscreening är ett allvarligt problem (Overdiagnosis in mammography screening is a serious problem). *Läkartidningen* 47:3180.
- Gøtzsche, P.C., and M. Nielsen. 2009. *Screening for breast cancer with mammography (review)*. Copenhagen: The Cochrane Collaboration, Wiley.
- Gustavson, K.-H. 1989. The prevention and management of autosomal recessive conditions. Main example: Alpha-1 antitrypsin deficiency. *Clinical Genetics* 36: 327–332.
- Hall, A., A. Bostanci, and C.F. Wright. 2010. Non-invasive prenatal diagnosis using cell-free fetal DNA technology: Applications and implications. *Public Health Genomics* 13:246–255.
- Hampton, M.L., J. Anderson, B.S. Lavizzo, and A.B. Bergman. 1974. Sickle-cell “nondisease”. *American Journal of Diseases of Children* 128:58–61.
- Häyry, M., and T. Takala. 2000. Genetic ignorance, moral obligations and social duties. *Journal of Medicine and Philosophy* 1:107–113.
- Hempel, C.G. 1967. *Philosophy of natural science*. Upper Saddle River, NJ and Harlow: Prentice Hall.
- Hernández, E.R. 2009. What next for preimplantation genetic screening? Beyond Aneuploidy. *Human Reproduction* 24(7):1538–1541.
- Hildt, E. 1999. Some reflections on the use of the term ‘prevention’ in reproductive medicine. In *Genetics in human reproduction*, eds. E. Hildt and S. Graumann, 243–250. Aldershot: Ashgate.
- Hoedemaekers, R. 1999. Genetic screening and testing. A moral map. In *The ethics of genetic screening*, eds. R. Chadwick et al. Dordrecht: Kluwer Academic Publishers.
- Hoffman, R.M. 2010. Randomized trial results did not resolve controversies surrounding prostate cancer screening. *Current Opinion in Urology* 20:189–193.
- Hoffman, R.M., M.P. Couper, B.J. Zikmund-Fisher, C.A. Levin, M. McNaughton-Collins, D.L. Helitzer, et al. 2010. Prostate cancer screening decisions: Results from the National Survey of Medical Decisions (DECISIONS study). *Archives of Internal Medicine* 169:1611–1618.

- Holm, S. 1999. There is nothing special about genetic information. In *Genetic information: Acquisition, access and control*, eds. A.R. Thompson and R. Chadwick, 97–103. New York, NY: Kluwer Academics/Plenum Publishers.
- Hugosson, J., S. Carlsson, G. Aus, S. Bergdahl, A. Khatami, P. Lodding, et al. 2010. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. *Lancet Oncology* 11:725–732.
- Ilic, D., D. O'Connor, S. Green, and T. Wilt. 2008. *Screening for prostate cancer (Review)*. Copenhagen: The Cochrane Collaboration, Wiley.
- Infertility Resources Website*. Internet portal to US commercial providers of assisted reproductive technologies and PGD. Online access: <http://www.ihr.com/infertility/provider/preimplantation-genetic-diagnosis-pgd.html>. Last accessed 29 Oct 2010.
- Ioannou, P. 1999. Thalassemia prevention in Cyprus. Past, present and future. In *The ethics of genetic screening*, eds. R. Chadwick, et al. Dordrecht: Kluwer Academics Publishers.
- Jenssen Hagerman, R., and P.J. Hagerman. (eds.) 2002. *Fragile X syndrome: Diagnosis, treatment, and research*, 3rd edition. Baltimore, MD: Johns Hopkins University Press.
- Juengst, E.T. 2003. Enhancement uses of medical technology. In *Encyclopedia of bioethics*, 3rd edition, ed. S.G. Post. New York, NY: Macmillan Reference USA.
- Justman, S. 2010. Uninformed consent: Mass screening for prostate cancer. *Bioethics*, Article first published online: 28 Jun 2010, doi: 10.1111/j.1467-8519.2010.01826.x.
- Juth, N. 2005. *Genetic information – values and rights: The morality of presymptomatic genetic testing*. Göteborg: Acta Universitatis Gothoburgensis.
- Juth, N., and C. Munthe. 2007. Screening: Ethical aspects. In *Principles of health care ethics*, 2nd edition, eds. R.E. Ashcroft, A. Dawson, H. Draper, and J.R. McMillan, 607–616. Chichester: Wiley.
- Kessler, S. 1997. Psychological aspects of genetic counseling. XI. Nondirectiveness revisited. *American Journal of Medical Genetics* 72:164–171.
- Kinzler, W.L., K. Morrell, and A.M. Vintzileos. 2002. Variables that underlie cost efficacy of prenatal screening. *Obstetrics and Gynecology Clinics of North America* 29:277–286.
- Kligman, G. 1998. *The politics of duplicity: Controlling reproduction in Ceausescu's Romania*. Berkeley and Los Angeles, CA: University of California Press.
- Kottow, M.H. 2002. Who is my brother's keeper? *Journal of Medical Ethics* 28:24–27.
- Lamont, J., and C. Favor. 2007. Distributive justice. In *Stanford encyclopedia of philosophy*, ed. E.N. Zalta. Stanford, CA: Stanford University. Available online: <http://plato.stanford.edu/entries/justice-distributive/>. Last accessed 1 Nov 2010.
- Levy, J. 1980. Vulnerable children: Parents' perspectives and the use of medical care. *Pediatrics* 65:956–963.
- Linnane, E., A. Paul, and R. Parry. 1999. Screening of newborn infants for cholestatic hepatobiliary disease. Does test fulfil screening criteria? *BMJ* 319:1435.
- Locke, J. 1689. *Two treatises of government*, ed. P. Laslett. New York: Cambridge University Press, 1988.
- Loeber, G., D. Webster, and A. Aznarez. 1999. Quality evaluation of newborn screening programs. *Acta Paediatrica* 432:3–6.
- Lun, F.M., N.B. Tsui, K.C. Chan, T.Y. Leung, T.K. Lau, P. Charoenkwan, et al. 2008. Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and

- relative mutation dosage on DNA in maternal plasma. *Proceedings of the National Academy of Sciences of the United States of America* 50:1990–1995.
- Malmqvist, E., G. Helgesson, J. Lehtinen, K. Natunen, and M. Lehtinen. 2010. The ethics of implementing human papillomavirus vaccination in developed countries. *Medicine, Health Care, and Philosophy* 14:19–27.
- March, J.G., and J.P. Olsen. 1989. *Rediscovering institutions: The organizational basis of politics*. New York, NY: Free Press.
- Marteau, T., and M. Richards. (eds.) 1996. *The troubled helix: Social and psychological implications of the new human genetics*. Cambridge: Cambridge University Press.
- McNamee, M., A. Müller, I. van Hilvoorde, and S. Holm. 2009. Genetic testing and sports medicine ethics'. *Sports Medicine* 39(5):339–344.
- McPherson, K. 2010. Should we screen for breast cancer? *BMJ* 341:233–234.
- Meade, N., and P. Bower. 2000. Patient-centeredness: A conceptual framework and review of the empirical literature. *Social Science & Medicine* 51:1087–1110.
- Mill, J.S. 1859. *On liberty*. Suffolk: Penguin Books, 1974.
- Mohamed, K., R. Appleton, and P. Nicolaides. 2000. Delayed diagnosis of Duchenne muscular dystrophy. *European Journal of Paediatric Neurology* 4(5):219–223.
- Moran, N.E., D. Shickle, C. Munthe, K. Dierickx, C. Petrini, F. Piribauer, et al. 2006. Are compulsory immunisation and incentives to immunise effective ways to achieve herd immunity in Europe? In *Ethics and infectious disease*, eds. M. Selgelid and M. Battin. London: Blackwell.
- Munthe, C. 1996. *The moral roots of prenatal diagnosis. Ethical aspects of the early introduction and presentation of prenatal diagnosis in Sweden*. Göteborg: Centrum för forskningsetik.
- Munthe, C. 1999. *Pure selection. The ethics of preimplantation genetic diagnosis and choosing children without abortion*. Göteborg: Acta Universitatis Gothoburgensis.
- Munthe, C. 2005. Ethical aspects of controlling genetic doping. In *Genetic technology and sport: Ethical questions*, eds. C. Tamburrini and T. Tännjö, 107–125. London and New York, NY: Routledge.
- Munthe, C. 2007. Preimplantation genetic diagnosis: Ethical aspects. In *Encyclopedia of life sciences*. Chichester: Wiley.
- Munthe, C. 2008. The goals of public health: An integrated, multidimensional model. *Public Health Ethics* 1(1):39–53.
- Munthe, C., L. Sandman, and D. Cutas. 2011. Person centred care and shared decision making: Implications for ethics, public health and research. *Health Care Analysis* 19, online first. doi: 10.1007/s10728-011-0183-y.
- Munthe, C., J. Wahlström, and S. Welin. 1998. Fosterdiagnostikens moraliska rötter. Goda handikappomsorger avgörande för den etiska kvaliteten (The moral roots of prenatal diagnosis. Good disability care crucial for the ethical quality). *Läkartidningen (Physician's Review)* 95:750–753.
- Murray, C.J.L., J.A. Salomon, C.D. Mathers, and A.D. Lopez. 2002. *Summary measures of population health: Concepts, ethics, measurement and applications*. Geneva: WHO.
- Myriad Genetics Website*. Online access: http://www.myriadtests.com/index.php?page_id=80. Last accessed 29 Oct 2010.
- Nadel, A.S., and M.L. Likhite. 2009. Impact of first-trimester aneuploidy screening in a high-risk population. *Fetal Diagnosis and Therapy* 26(1):29–34.

- Natowicz, M. 2005. Newborn screening – setting evidence-based policy for protection. *New English Journal of Medicine* 9:867–870.
- Neal, D.E. 2010. PSA testing for prostate cancer improves survival – but can we do better? *The Lancet Oncology* 11:702–703.
- Newschaffer, C.J., K. Otani, M.K. McDonald, and L.T. Penberthy. 2000. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. *Journal of the National Cancer Institute* 92:613–621.
- Nijssingh, N. 2007. Informed consent and the expansion of newborn screening. In *Ethics, prevention and public health*, eds. A. Dawson and M. Verweij. Oxford: Oxford University Press.
- Nilsson, T., C. Munthe, C. Gustavson, A. Forsman, and H. Anckarsäter. 2009. The precarious practice of forensic psychiatric risk assessment. *International Journal of Law and Psychiatry* 32:400–407.
- Nordenfelt, L. 2003. On the evolutionary concept of health: Health as natural function. In *Dimensions of health and health promotion*, eds. L. Nordenfelt and P.E. Liss, 37–56. Amsterdam: Rodopi Press.
- Nozick, R. 1974. *Anarchy, state and Utopia*. New York, NY: Basic Books.
- The Nuffield Council on Bioethics. 1993. *Genetic screening and ethical issues*. London: The Nuffield Council on Bioethics.
- The Nuffield Council on Bioethics. 2010. *Medical profiling and online medicine: The ethics of 'personalised healthcare' in a consumer age*. Nuffield Council on Bioethics, London. Available online: <http://www.nuffieldbioethics.org/personalised-healthcare-0>. Last accessed 31 Oct 2010.
- Pandor, A., J. Eastman, C. Beverley, J. Chilcott, and S. Paisley. 2004. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: A systematic review. *Health Technology Assessment* 8:1–134.
- Parens, E., and A. Asch. 2000. *Prenatal testing and disability rights*. Washington, DC: Georgetown University Press.
- Parker, G. 1983. *Parental overprotection: A risk factor in psychosocial development*. New York, NY: Grune & Stratton.
- Persad, G., A. Wertheimer, and E.J. Emanuel. 2009. Principles for allocation of scarce medical interventions. *Lancet* 373:423–431.
- Platt Walker, A. 1998. The practice of genetic counselling. In *A guide to genetic counselling*, ed. D.L. Baker, 1–20. Chichester: Wiley-Liss Inc.
- Post, S.G., J.R. Botkin, and P. Whitehouse. 1992. Selective abortion for familial Alzheimer disease? *Obstetrics and Gynaecology* 79:794–798.
- The President's Council on Bioethics. 2008. *The changing moral focus of newborn screening: An ethical analysis by the President's council on bioethics*. Washington, DC: The President's Council on Bioethics.
- Radetzki, M., M. Radetzki, and N. Juth. 2003. *Genes and insurance: Ethical, legal and economic issues*. Cambridge: Cambridge University Press.
- Ravitsky, V. 2009. Non-invasive prenatal diagnosis: An ethical imperative. *Nature Reviews Genetics* 10:733.
- Rawls, J. 1972. *A theory of justice*. London: Oxford University Press.
- Renner, I. (ed.) 2006. Experience of pregnancy and prenatal diagnosis. *Bundeszentrale für gesundheitliche Aufklärung* [online] <http://www.bzga.de/?uid=25d093aacb9296ea646b087b68c27996&id=medien&sid=88&idx=1496>. Accessed Nov 2010.

- Rhodes, R. 1998. Genetic links, family ties and social bonds: Rights and responsibilities in the face of genetic knowledge. *Journal of Medicine and Philosophy* 23:10–30.
- Rhodes, R. 2005. Justice in medicine and public health. *Cambridge Quarterly of Healthcare Ethics* 14(1):13–26.
- Robertson, S., and J. Savulescu. 2001. Is there a case in favour of predictive genetic testing in young children? *Bioethics* 15:26–49.
- Rose, G. 1992. *The strategy of preventive medicine*. Oxford: Oxford University Press.
- Rosen, G. 1993. *A history of public health, expanded edition*. Baltimore, MD: Johns Hopkins University Press.
- Rowland, A.S., D.M. Umbach, K.E. Catoe, S. Long, D. Rabiner, A.J. Naftel, R. Panke Faulk, and D.P. Sandler. 2001. Studying the epidemiology of attention-deficit hyperactivity disorder: Screening method and pilot results. *Canadian Journal of Psychiatry* 46:931–940.
- Saltvedt, S. 2005. *Prenatal diagnosis in routine antenatal care – A randomised controlled trial*. Stockholm: Kongl Carolinska Medico Chirurgiska Institutet.
- Salwén, H. 2003. *Hume's law: An essay on moral reasoning*. Stockholm: Almqvist & Wiksell International.
- Sandén, M.-L., and P. Bjurulf. 1988. Pregnant women's attitudes for accepting or declining a serum-alpha-fetoprotein test. *Scandinavian Journal of Social Medicine* 16:265–271.
- Sandman, L., and C. Munthe. 2009. Shared decision making and patient autonomy. *Theoretical Medicine and Bioethics* 30(4):289–310.
- Sandman, L., and C. Munthe. 2010. Shared decision making, paternalism and patient choice. *Health Care Analysis* 18(1):60–84.
- Savulescu, J. 2005. Compulsory genetic testing for APOE Epsilon 4 and boxing. In *Genetic technology and sport: Ethical questions*, eds. C. Tamburrini and T. Tännsjö, 136–146. London and New York, NY: Routledge.
- Schmitz, D., C. Netzer, and W. Henn. 2009. An offer you can't refuse? Ethical implications of non-invasive prenatal diagnosis. *Nature Reviews Genetics* 10:515.
- Schröder, F.H., J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, V. Nelen, et al. 2009. Screening and prostate-cancer mortality in a randomized European study. *The New England Journal of Medicine* 13:1320–1328.
- Scott, R. 2005. Prenatal testing, reproductive autonomy, and disability interests. *Cambridge Quarterly of Healthcare Ethics* 14:65–82.
- Segall, S. 2010. *Health, luck, and justice*. Princeton, NJ: Princeton University Press.
- Shattuck-Eidens, D., et al. 1997. BRCA1 Sequence analysis in women at high risk for susceptibility mutations. *Journal of the American Medical Association* 15: 1242–1250.
- Shickle, D. 1999. The Wilson and Jungner principles of screening and genetic testing. In *The ethics of genetic screening*, eds. R. Chadwick et al. Dordrecht: Kluwer Academic Publishers.
- Shickle, D., and I. Harvey. 1993. Inside-out, back-to-front: A model for clinical population genetic screening. *Journal of Medical Genetics* 30:580–582.
- Shickle, D., E. Richardson, F. Day, C. Munthe, A. Jovell, H. Gylling, et al. 2007. *Public policies, law and bioethics: A framework for producing public health policy across the European Union*. Leeds: University of Leeds. Online access: http://www.leeds.ac.uk/lihs/ihsphr_ph/documents/EurophenFullReport.pdf. Accessed 25 Oct 2010.

- Shiloh, S. 1996. Decision-making in the context of genetic risk. In *The troubled helix: Social and psychological implications of the new human genetics*, eds. T. Marteau and M. Richards, 82–103. Cambridge: Cambridge University Press.
- Skinner, D., K. Sparkman, and D.B. Bailey Jr. 2003. Screening for fragile X syndrome: Patient attitudes and perspectives. *Genetics in Medicine* 5:378–384.
- Skrabanek, P. 1985. False premises and false promises of breast cancer screening. *The Lancet* 326(8446):94–95.
- Skrabanek, P. 2000. *False premises, false promises: Selected writings of Peter Skrabanek*. Glasgow: Tarragon Press.
- Smith, D.S., P.A. Humphrey, and W.J. Catalona. 1997. The early detection of prostate carcinoma with prostate specific antigen: The Washington University experience. *Cancer* 80:1853–1856.
- Smith Iltis, A. 2001. Organizational ethics and institutional integrity. *HEC Forum* 13(4):317–328.
- Sobel, S.K., and D.B. Cowan. 2000. Impact of genetic testing for Huntington disease on the family system. *American Journal of Medical Genetics* 90:49–59.
- State of Michigan. 1978. *Public health code, Act 368 of 1978*. Lansing, MI: The State of Michigan.
- Stein, R. 2010a. Company plans to sell genetic testing kit at drugstores. *Washington Post*, 11 May 2010. Available online: <http://www.washingtonpost.com/wp-dyn/content/article/2010/05/10/AR2010051004904.html>. Last accessed 29 Oct 2010.
- Stein, R. 2010b. Walgreens won't sell over-the-counter genetic test after FDA raises questions. *Washington Post*, 13 May 13 2010. Available online: <http://www.washingtonpost.com/wp-dyn/content/article/2010/05/12/AR2010051205156.html>. Last accessed 29 Oct 2010.
- Sutton, V.R. 2002. Tay-Sachs disease. Screening and counseling families at risk for metabolic disease. *Obstetrics and Gynecology Clinics of North America* 29:287–296.
- Swedish Organized Service Screening Evaluation Group. 2006. Reduction in breast cancer mortality from organized service screening with mammography. Further confirmation with extended data. *Cancer Epidemiology, Biomarkers and Prevention* 15:45–51.
- ten Have, H. 2000. Genetics and culture. In *Bioethics in a European perspective*, eds. H. ten Have and B. Gordijn. Nijmegen: Programme of the European Masters in Bioethics.
- Thelin, T., T. Sveger, and T.F. McNeil. 1996. Primary prevention in a high-risk group: Smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). *Acta Paediatrica* 85:1207–1212.
- Thomasgard, M. 1998. Parental perception of child vulnerability, overprotection, and psychological characteristics. *Child Psychiatry and Human Development* 28: 223–240.
- Tännsjö, T. 1999. *Coercive care. The ethics of choice in health and medicine*. London: Routledge.
- Törnberg, S., and L. Nyström. 2009a. Skrämselfpropaganda om mammografi (Propaganda with intention to scare regarding mammography). *Läkartidningen* 42:2664–2665.
- Törnberg, S., and L. Nyström. 2009b. Värre med utredningsorsakad oro än förtidig död i bröstcancer? (Is it worse with examination-induced anxiety than premature death in cancer?). *Läkartidningen* 45:3018.

- U.S. Preventive Services Task Force. 2008. Screening for prostate cancer: US. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 149:185–191.
- Vahab Saadi, A., P. Kushtagi, P.M. Gopinath, and K. Satyamoorthy. 2010. Quantitative fluorescence polymerase chain reaction (QF-PCR) for prenatal diagnosis of chromosomal aneuploidies. *International Journal of Human Genetics* 10(1–3):121–129.
- van den Heuvel, A., L. Chitty, E. Dormandy, A. Newson, Z. Deans, S. Attwood, S. Haynes, and T.M. Marteau. 2009. Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals. *Patient Education and Counseling* 78:24–28.
- van der Schoot, C.E., S. Hahn, and L.S. Chitty. 2008. Non-invasive prenatal diagnosis and determination of fetal Rh status. *Seminars in Fetal & Neonatal Medicine* 13, 63–68.
- Verweij, M. 2000. *Preventive medicine between obligation and aspiration*. Dordrecht, Boston, MA and London: Kluwer Academic Publishers.
- Wakefield, J.C. 1992. The concept of mental disorder. On the boundary between biological facts and social values. *American Psychologist* 4(3):373–388.
- Walzer, M. 1983. *Spheres of justice. In defence of pluralism and equality*. New York, NY and London: Basic Books.
- WHO. 1998. *Proposed international guidelines on ethical issues in medical genetics and the provision of genetic services*. Geneva: WHO 15–16 Dec 1997.
- Wilcken, B. 2009. Cystic fibrosis: Refining the approach to newborn screening. *The Journal of Pediatrics* 155(5):605–606.
- Wilcken, B., V. Wiley, J. Hammond, and K. Carpenter. 2003. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. *The New England Journal of Medicine* 23:2304–2312.
- Wilkinson, S. 2003. *Bodies for sale. Ethics and exploitation in the human body trade*. London: Routledge.
- Wilson, J. 2009. Towards a normative framework for public health ethics and policy. *Public Health Ethics* 2(2):184–194.
- Wilson, J.M.G., and G. Jungner. 1968. Principles and practice of screening for disease. *Public Health Papers*, WHO No. 34, Geneva.
- World Medical Association. 1964–2008. *Declaration of Helsinki: Ethical principles for medical research involving human subjects*. Available online: <http://www.wma.net/en/30publications/10policies/b3/17c.pdf>. Accessed 25 Oct 2010.
- Wright, C.F., and H. Burton. 2008. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. *Human Reproduction Update* 1:139–151.
- Wright, C.F., and L.S. Chitty. 2009. Cell-free fetal DNA and RNA in maternal blood: Implications for safer antenatal testing. *BMJ* 339:b2451. doi: 10.1136/bmj.b2451.
- Zackrisson, S., I. Andersson, L. Janzon, J. Manjer, and J.P. Garne. 2006. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: Follow-up study. *BMJ* 332:689–692.
- Zamerowski, S.T., M.A. Lumley, R.A. Arreola, K. Dukes, and L. Sullivan. 2001. Favorable attitudes toward testing for chromosomal abnormalities via analysis of fetal cells in maternal blood. *Genetics in Medicine* 3:301–309.

Index

A

Ablon, J, 55
Abortion, 17, 34–38, 40, 65, 73–76, 104–105, 141, 154
ACMG (American College of Medical Genetics), 43, 49–51, 60, 110, 112
Adelswärd, V, 68
ADHD (attention-deficit/hyperactivity disorder), 55, 160
Adolescent screening, 53–58, 75–77, 87, 99, 160
Adverse selection, 59
AFP (amniotic fluid α -fetoprotein), 64–65
Ahlenius, H, vi
Alzheimer's disease, 68
Amniocentesis, 35, 61, 100
Andermann, A, 3
Annes, JP, 142
Asch, A, 17, 36–39, 83
Ashcroft, RE, v
ATD (Alpha-1 Antitrypsin Deficiency), 76–77, 99, 128, 152, 160
Autonomy, 7, 10, 13, 17–18, 21–29, 33–34, 36–37, 39–40, 42, 44–46, 48–49, 54, 56–58, 60, 64, 66–67, 69, 73–78, 80, 82–89, 91–98, 103–108, 110–111, 114, 121, 127–130, 132–134, 136, 138, 140, 148, 150, 152, 156, 158–161

B

Bailey, DB, 108, 110–113
Baily, MA, 110–111, 153
Barry, B, 147
Battin, MP, 21

Beauchamp, TL, 23–25, 38, 44, 84, 86, 125
Benn, PA, 107
Biotinidase deficiency, 43, 45
Bjurulf, P, 65
Björck, E, vi, 112
Boorse, C, 150
Bower, P, 17
Brandon, K, 60
Broberg, G, 42
Breast cancer, 5–6, 58, 61, 65–66, 71, 105, 114–116, 118–120, 157
Brülde, B, vi
Buchanan, A, 34, 38, 132
Bui, TH, 35–36
Burton, H, 100–101, 103

C

Cancer, 5–6, 58, 61, 65–68, 71, 88, 90, 100, 105, 114–120, 122–126, 155, 157
Cardiac disease, 66
Cardio-vascular disease, 68
Carrier detection, 33, 62, 84
Cascade genetic testing, 9, 158
cffNA (cell-free nucleic acid), 100, 103
Chadwick, R, 8–9, 33, 43
Chalmers, D, 3
Chapman, AR, 107
Childress, JF, 2, 23–25, 38, 44, 84, 86, 125, 130
Chiu, RWK, 101
CIOMS (Council for international organizations of medical sciences), 130

- Chromosomal (aberration, condition, disease, or disorder), 9, 16, 33, 35, 40, 62, 72, 100, 102, 107, 111–112, 154
- Clarke, A, 26, 65
- Cochrane collaboration, 114–115, 120, 123
- Coggon, J, 133
- Communicable disease, 9, 20, 66, 86, 128, 131, 134, 137–141, 157, 162
- Confidentiality, 91
- Congenital hypothyroidism, 43
- Connor, M, 32, 61, 68, 108
- Consequentialist, 10
- Cost-benefit analysis, 10
- Counselling, 5, 10–11, 17, 19–20, 24, 27, 33, 47–48, 52, 54, 57–58, 60, 67, 73, 75–77, 79–81, 84–85, 87–95, 97–98, 101, 103–105, 110, 112–114, 121–122, 133, 140–141, 145, 151–156, 160–161
- Coutts, MC, 140
- Cowan, DB, 90
- Cutas, D, vi
- Cut-off point, 56, 102, 122, 156
- CVS (chorionic villus sampling), 35, 61, 100
- Cystic fibrosis, 9, 16, 62, 71, 84, 100, 111
- D**
- Daniels, N, 147
- Danish council of ethics, 7, 96
- Davis, TC, 112
- Dawson, A, 1–2, 26, 46, 54, 99
- Deans, Z, 108
- Declaration of Helsinki, 130
- de Jong., A, 102, 106
- Denham, JW, 67
- Dew-Hughes, D., 110
- Diabetes, 18, 66, 68, 70, 72
- Diagnostic odyssey, 110–111, 113
- Diagnosis, 4, 6, 8, 10, 17, 21–22, 27, 33–41, 49, 61–63, 65–66, 76, 78, 85, 90, 99–108, 110–111, 115–118, 120, 122–124, 140–142, 151–156, 159, 162
- Draper, H., v
- DTC (direct to consumer) genetic testing, 137, 141–147, 156, 158, 162
- Down syndrome, 107–108, 157
- Duchenne muscular dystrophy, 43
- Duffy, SW, 114, 119
- E**
- Eddy, DM, 17
- Employers, 59, 79, 129, 160
- ERSPC (the European randomized study of screening for prostate cancer), 123–124
- ESHG (European Society of Human Genetics), 9, 82, 85, 88
- Esserman, L, 117
- Evans, JP, 142
- F**
- Fang, F, 124
- Favor, C, 147
- Favre, R, 105
- FDA (food and drug administration), 143–144
- Ferguson-Smith, M, 32, 61, 68, 108
- Financial incentives, 81
- FMR-1 gene, 109
- Fragile X, 5, 32, 52, 62, 71, 99, 108–114, 152, 162
- Fraser, FC, 87–89
- Freedman, DA, 114
- Friedman, M, 144–146
- Friedman Ross, L, 47, 131
- Funding, 70, 81, 95–97
- FXTAS, 109
- G**
- Genetic carrier screening, 8
- Genetic counselling, 84, 87–93, 113, 140, 145
- Genetic disease, 16, 66, 71, 92, 102, 111
- Genetic integrity act, 61
- Genetics, 2, 7, 35, 43, 87–93, 113, 146
- Gianroli, L, 63
- Glover, J, 23, 132
- Gregg, AR, 9, 71
- Gustavson, KH, 76
- Gøtzsche, PC, 67, 114–119, 121

H

Hall, A, 106–107
 Hampton, ML, 20
 Harvey, I, 9
 Häyry, M, 84
 Harm, 23, 32, 44–45, 58, 65, 86, 117–118
 Health insurance, 56, 59–60, 84
 Helgesson, G, vi
 Hempel, CG, 140
 Hermerén, G, vi
 Hernández, ER, 63
 Hildt, E, 35
 HIV (human immunodeficiency virus), 9, 15, 20, 88
 Hoedemaekers, R, 7, 10, 24, 26–27, 82–84
 Hoffman, AJ, vi, 45
 Hoffman, RM, 123, 125
 Holm, S, 88
 HPV (human papillomavirus), 99
 Hugosson, J, 124

I

Ilic, D, 123
 Iatrogenic abortion, 101
 Infectious disease, 2, 21, 139–140
 Infertility resources website, 145
 Informed consent, 23, 25, 45–49, 54, 79, 81–87, 97–98, 105–106, 108, 111–112, 121, 125, 127, 131–134, 152–153, 155, 160–161
 Institutional approach (to health-care ethics), 6, 135–150, 154, 157, 162
 Institutional integrity, 136
 Invasive testing, 105–106
 Invasive prenatal testing, 62, 104–105
 Insurance companies, 59, 79, 160
 Ioannou, P, 9, 33
 IVF (in vitro fertilization), 63, 142, 145

J

Jenssen Hagerman, R, 110
 Juengst, ET, 111
 Jungner, G, 3–6, 9–10, 14, 27, 31–32, 44, 60, 63, 66, 73, 115, 117, 122, 129, 149–157, 159, 162

Justice, 7, 13, 27–29, 96, 138, 147–149, 152, 156
 Justman, S, 96, 117, 125, 155
 Juth, N, 17, 22–25, 59–60, 70, 84–86, 88, 91, 104–105, 113–114
 Jörgensen, KJ, 114, 117, 119, 121

K

Kessler, S, 91–92
 Kinzler, WL, 8, 10
 Kligman, G, 141
 Klinefelter's, 33, 112
 Kottow, MH, 132

L

Lamont, J, 147
 Levy, J, 55
 Life expectancy, 14, 18, 97
 Life insurance, 56–57, 59–60, 66, 79, 84, 113, 160
 Life-style, 16–18, 66–67, 75–76
 Likhite, ML, 62
 Linnane, E, 3
 Locke, J, 23
 Loeber, G, 43
 Lun, FM, 101
 Lynöe, N, vi

M

Malmqvist, E, 99
 Mammography, 5, 58, 61, 66–67, 97, 99, 114–122, 124–126, 129, 132, 155, 162
 Mammography screening, 5, 58, 61, 99, 114–122, 124, 129, 132, 162
 March, JG, 120
 Marteau, T, 9
 Mastectomy, 15, 65, 116
 McNamee, M, 3
 McPherson, K, 117
 McMillan, J, v
 Medical ethics, 1–2, 17–18, 24, 38, 40, 45, 50, 56, 91, 134
 Medicalise, 2
 Medicalization, 46
 Mental disability, 32, 108
 Mill, JS, 23
 Miscarriage, 61–62, 100, 102, 104–105

- Mohamed, K, 43
 Monogenetic, 16, 71, 101–102, 109, 111
 Moran, NE, 54
 Multifactorial, 68, 70–72, 111
 Munthe, C, 2–3, 17, 22, 24–26, 28, 35–37, 39, 56, 63, 74, 82–84, 86, 91, 93, 95, 107, 130, 140
 Murray, CJL, 14
 Murray, TH, 110–111, 153
 Myriad genetics website, 146
- N**
 Nadel, AS, 62
 Natowicz, M, 50
 Neal, DE, 122, 124
 Newschaffer, CJ, 119
 Nijsingh, N, 43, 46–48, 54, 86
 NIPD (non-invasive prenatal diagnosis), 100–108, 162
 Neonatal screening, 5, 8, 16, 42–54, 66, 71, 78–79, 85–86, 94–95, 97, 99, 108–114, 122, 131–132, 137, 140, 145, 152, 154, 157, 159–160, 162
 Newson, AJ, 108
 Non-directiveness, 91–93, 98, 161
 Nordenfelt, L, 150
 Nordenskjöld, M, 36
 Normalization, 106
 Nozick, R, 23
 Nuffield council of bioethics, 143
 Nyström, L, 114–115, 117–119, 121
- O**
 Obstetric ultrasound, 8, 37, 40, 62, 100
 Overdiagnosis, 116–118, 120, 122, 124, 153, 155
 Overtreatment, 61, 66–67, 72, 116–122, 124, 153
- P**
 Pandemics, 2, 21, 26, 128, 138–139, 151, 157
 Pandor, A, 49, 51
 Parens, E, 17, 36–39, 83
 Parkinson's, 109
 Pedigree, 89
 Penetrance, 70, 71, 109
- Persad, G, 147
 PGD (preimplantation genetic diagnosis), 63, 142, 145
 PKU (phenylketonuria), 6, 16, 32, 43, 45, 51, 66, 72, 99, 109, 111–112, 143
 Platt Walker, A, 84, 88–90
 Post, SG, 32
 Prenatal screening, 9, 21, 26, 33–42, 44, 47, 49, 52, 57–58, 62, 65, 72–76, 78, 80–83, 86–87, 101–108, 127, 129, 132, 137–138, 141, 154, 159, 161–162
 President's council on bioethics, 45
 Presymptomatic genetic testing, 55, 145
 Prevalence, 32–33, 35–36, 39, 44, 50, 52, 55, 65–66, 78, 107–108, 127, 138–139, 150–151, 159, 162
 Privacy, 91
 Prostate cancer, 5, 58, 66–67, 117, 122–126
 Population, 1, 3, 5–11, 14–15, 20–22, 25–26, 29, 32–33, 41–42, 46, 53–54, 56–57, 60–61, 66, 68, 70–71, 74–78, 80, 85–87, 94–95, 97, 112, 114–115, 117, 123, 127–132, 134, 137–140, 143, 147, 151, 153–154, 156–160
 PSA (prostate-specific antigene), 5, 58, 66–67, 99, 117, 122–126, 156, 162
 PSA screening, 5, 99, 117, 122–126, 156, 162
 Psychological well-being, 17–18, 29, 66, 85, 96, 158
 Public health, 1–3, 7–8, 10, 14–15, 20–22, 25–29, 32, 35–36, 39, 41, 46–47, 49, 52–53, 56, 58, 60, 65–67, 74, 76, 86–87, 95–98, 107, 127–135, 137, 139–141, 145, 147, 152, 154, 157–158, 160–162
 Public health ethics, 2, 96, 129–130, 135, 137, 145
- Q**
 QF-PCR, 35–36, 39, 106
 Quality of life, 5, 18, 38, 44, 60, 123
- R**
 Radetzki, M, 59–60
 Ravitsky, V, 101, 103–104

Rawls, J, 27, 147
 Real cancer (invasive cancer), 115
 Renner, I, 105
 Rhodes, R, 2, 24
 Richards, M, 9
 Risk, absolute, 69, 86, 146
 Risk, relative, 69–70, 121, 146, 156
 Robertson, S, 53
 Roll-Hansen, N, 42
 Rose, G, 15
 Rosen, G, 139
 Rowland, AS, 55

S

Sachs, L, 9, 35, 68
 Saltvedt, S, 62, 81, 104
 Salwén, H, 119
 Sanctity of life (the principle of), 36
 Sandén, ML, 65
 Sandman, L, 17, 22, 24, 26, 86, 93, 95
 Savulescu, J, 3, 53
 SCAD (short-chain acyl-CoA dehydrogenase deficiency), 51
 Schizophrenia, 68
 Schmitz, D, 40, 105
 Schröder, FH, 123
 Scott, R, 38
 Screening, concept of, 5–11, 142
 Screening of children, 19, 53, 56–57, 79
 Segall, S, 106
 Severity of disease, 32
 Shattuck-Eidens, D, 71
 Shickle, D, 2, 7–10, 17, 27, 60, 68, 130
 Shiloh, S, 68, 92
 Sick cell anemia, 9, 20, 65
 Simpson, JL, 9, 71
 Sjöstrand, M, vi
 Skinner, D, 109
 Skrabanek, P, 114
 Smith, DS, 124
 Smith Iltis, A, 136
 Sobel, SK, 90
 Social science perspective, 6, 132–134, 148
 Specification creep, 106–107
 State of Michigan, 47

Stein, R, 143
 Sterilisation, 42, 141
 Stigmatisation, 38, 46, 52, 55–57, 66, 76–77, 79, 107, 128, 160
 Sutton, VR, 9
 Swedish organized service screening evaluation group, 118

T

Takala, T, 84
 Tandem mass spectrometry, 49–50, 112
 Tay-Sachs, 9
 Ten Have, H, 91, 94
 Thalassemia, 9, 33
 Thelin, T, 77
 Thomasgard, M, 55
 Treatment, 4, 6–7, 10–11, 14–21, 23, 31, 33, 40, 43, 47, 49–50, 52–53, 55–56, 59, 61, 65–67, 70, 72–77, 80–81, 85, 88, 90, 92, 98, 110, 115–124, 127, 135, 150–155, 157, 159–161
 Triple X syndrome, 112
 Turner, 33, 112
 Törnberg, S, 114–115, 117–119, 121

V

Vahab Saadi, A, 35
 van den Heuvel, A, 106
 van der Schoot, CE, 101
 Verweij, M, 1–2, 15–16, 26, 46
 von Döbeln, U, 50–51

W

Wahlström, J, vi
 Wakefield, JC, 150
 Walzer, M, 134, 144, 146
 Weisstub, D, v
 Well-being, 10, 13, 17–22, 24, 27–29, 45, 57, 66, 72, 85–87, 92–93, 96, 98, 104, 150, 152, 158, 161
 Werdnig-Hoffman disease, 35
 Wessel, M, vi
 WHO (World health organization), 3, 88, 117
 Wilcken, B, 43, 49–50, 71
 Wilkinson, S, 83

Wilson, JMG, 3–6, 9–10, 14, 27, 31–32,
44, 60, 63, 66, 73, 115, 117, 122,
129–130, 149–157, 159, 162
Wilson and Jungner criteria, 3–5, 117,
129, 149–157, 162
World medical association, 125, 130
Wright, CF, 100–101, 103

X

X-linked disorder, 109, 112
XXY, 112

Z

Zackrisson, S, 116
Zamerowski, ST, 106